Introduction: Diabetes is the leading cause of chronic kidney disease (CKD) and is associated with excessive cardiovascular morbidity and mortality. Anemia is common among those with diabetes and chronic kidney disease and greatly contributes to patient outcomes. Observational studies indicate that low hemoglobin levels in such patients may increase risk for progression of kidney disease and cardiovascular morbidity and mortality.
Objective: 1. Estimation of glycosylated hemoglobin (HbA1c) and hemoglobin level in patients with type II diabetes mellitus.
2. To determine the prevalence of anaemia in type 2 diabetes mellitus with or without chronic kidney disease.
Methodology: This is a descriptive analytical cross-sectional study carried out in Dhiraj Hospital, Piparia, Vadodara. A total no of 100 consecutive patients were enrolled; 25 patients having Diabetes, 25 patients having diabetes and chronic kidney disease, 25 patients having only chronic kidney disease but no diabetes and 25 patients neither having diabetes nor chronic kidney disease taken as a control group.
Results: Anemia was present in 37% diabetic patients, 17% in diabetic patients with chronic kidney disease, 3% in patients with only chronic kidney disease. Anaemia was significantly higher in patients with diabetes, chronic kidney disease and diabetes with chronic kidney disease.
Conclusion: Anemia was more prevalent in persons with diabetes and diabetes associated with chronic kidney disease compared to persons without diabetes. Therefore anemia may be particularly harmful in individuals with diabetes and chronic kidney disease. Correction of anemia may have a significant role in prevention of other diabetic complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.